Literature DB >> 26324264

GS-5806 inhibits pre- to postfusion conformational changes of the respiratory syncytial virus fusion protein.

Dharmaraj Samuel1, Weimei Xing2, Anita Niedziela-Majka2, Jinny S Wong3, Magdeleine Hung2, Katherine M Brendza2, Michel Perron2, Robert Jordan2, David Sperandio2, Xiaohong Liu2, Richard Mackman2, Roman Sakowicz2.   

Abstract

GS-5806 is a small-molecule inhibitor of human respiratory syncytial virus fusion protein-mediated viral entry. During viral entry, the fusion protein undergoes major conformational changes, resulting in fusion of the viral envelope with the host cell membrane. This process is reproduced in vitro using a purified, truncated respiratory syncytial virus (RSV) fusion protein. GS-5806 blocked these conformational changes, suggesting a possible mechanism for antiviral activity.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26324264      PMCID： PMC4604407          DOI： 10.1128/AAC.00761-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  23 in total

1.  VP-14637 ViroPharma.

Authors:  J McKimm-Breschkin
Journal:  Curr Opin Investig Drugs       Date:  2000-12

Review 2.  Prospects for the development of fusion inhibitors to treat human respiratory syncytial virus infection.

Authors:  Jean-François Bonfanti; Dirk Roymans
Journal:  Curr Opin Drug Discov Devel       Date:  2009-07

3.  pH-dependent changes in photoaffinity labeling patterns of the H1 influenza virus hemagglutinin by using an inhibitor of viral fusion.

Authors:  C Cianci; K L Yu; D D Dischino; W Harte; M Deshpande; G Luo; R J Colonno; N A Meanwell; M Krystal
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

4.  Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.

Authors:  Jose R Romero
Journal:  Pediatr Infect Dis J       Date:  2003-02       Impact factor: 2.129

5.  Soluble respiratory syncytial virus fusion protein in the fully cleaved, pretriggered state is triggered by exposure to low-molarity buffer.

Authors:  Supranee Chaiwatpongsakorn; Raquel F Epand; Peter L Collins; Richard M Epand; Mark E Peeples
Journal:  J Virol       Date:  2011-02-09       Impact factor: 5.103

6.  Binding of a potent small-molecule inhibitor of six-helix bundle formation requires interactions with both heptad-repeats of the RSV fusion protein.

Authors:  Dirk Roymans; Hendrik L De Bondt; Eric Arnoult; Peggy Geluykens; Tom Gevers; Marcia Van Ginderen; Nick Verheyen; Hidong Kim; Rudy Willebrords; Jean-François Bonfanti; Wouter Bruinzeel; Maxwell D Cummings; Herman van Vlijmen; Koen Andries
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-04       Impact factor: 11.205

7.  Cross-resistance mechanism of respiratory syncytial virus against structurally diverse entry inhibitors.

Authors:  Dan Yan; Sujin Lee; Vidhi D Thakkar; Ming Luo; Martin L Moore; Richard Karl Plemper
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-04       Impact factor: 11.205

8.  High morbidity and mortality in adults hospitalized for respiratory syncytial virus infections.

Authors:  N Lee; G C Y Lui; K T Wong; T C M Li; E C M Tse; J Y C Chan; J Yu; S S M Wong; K W Choi; R Y K Wong; K L K Ngai; D S C Hui; P K S Chan
Journal:  Clin Infect Dis       Date:  2013-07-21       Impact factor: 9.079

9.  Functional interactions between the fusion protein and hemagglutinin-neuraminidase of human parainfluenza viruses.

Authors:  X L Hu; R Ray; R W Compans
Journal:  J Virol       Date:  1992-03       Impact factor: 5.103

10.  Localization of a domain on the paramyxovirus attachment protein required for the promotion of cellular fusion by its homologous fusion protein spike.

Authors:  R Deng; Z Wang; A M Mirza; R M Iorio
Journal:  Virology       Date:  1995-06-01       Impact factor: 3.616
View more
  15 in total

Review 1.  Respiratory Syncytial Virus: Infection, Detection, and New Options for Prevention and Treatment.

Authors:  Cameron Griffiths; Steven J Drews; David J Marchant
Journal:  Clin Microbiol Rev       Date:  2017-01       Impact factor: 26.132

Review 2.  How I treat respiratory viral infections in the setting of intensive chemotherapy or hematopoietic cell transplantation.

Authors:  Alpana Waghmare; Janet A Englund; Michael Boeckh
Journal:  Blood       Date:  2016-03-11       Impact factor: 22.113

Review 3.  Antivirals targeting paramyxovirus membrane fusion.

Authors:  Erik M Contreras; Isaac Abrrey Monreal; Martin Ruvalcaba; Victoria Ortega; Hector C Aguilar
Journal:  Curr Opin Virol       Date:  2021-09-27       Impact factor: 7.090

4.  Molecular mechanism of respiratory syncytial virus fusion inhibitors.

Authors:  Michael B Battles; Johannes P Langedijk; Polina Furmanova-Hollenstein; Supranee Chaiwatpongsakorn; Heather M Costello; Leen Kwanten; Luc Vranckx; Paul Vink; Steffen Jaensch; Tim H M Jonckers; Anil Koul; Eric Arnoult; Mark E Peeples; Dirk Roymans; Jason S McLellan
Journal:  Nat Chem Biol       Date:  2015-12-07       Impact factor: 15.040

5.  GS-5806 Inhibits a Broad Range of Respiratory Syncytial Virus Clinical Isolates by Blocking the Virus-Cell Fusion Process.

Authors:  Michel Perron; Kirsten Stray; April Kinkade; Dorothy Theodore; Gary Lee; Eugene Eisenberg; Michael Sangi; Brian E Gilbert; Robert Jordan; Pedro A Piedra; Geoffery L Toms; Richard Mackman; Tomas Cihlar
Journal:  Antimicrob Agents Chemother       Date:  2015-12-14       Impact factor: 5.191

6.  Small molecule inhibits respiratory syncytial virus entry and infection by blocking the interaction of the viral fusion protein with the cell membrane.

Authors:  Wei Tang; Manmei Li; Yujun Liu; Ning Liang; Zhu Yang; Yanxiang Zhao; Shuai Wu; Sangwei Lu; Yaolan Li; Fenyong Liu
Journal:  FASEB J       Date:  2018-12-20       Impact factor: 5.834

Review 7.  Verdinexor Targeting of CRM1 is a Promising Therapeutic Approach against RSV and Influenza Viruses.

Authors:  Jennifer A Pickens; Ralph A Tripp
Journal:  Viruses       Date:  2018-01-21       Impact factor: 5.048

8.  Structure and immunogenicity of pre-fusion-stabilized human metapneumovirus F glycoprotein.

Authors:  Michael B Battles; Vicente Más; Eduardo Olmedillas; Olga Cano; Mónica Vázquez; Laura Rodríguez; José A Melero; Jason S McLellan
Journal:  Nat Commun       Date:  2017-11-16       Impact factor: 14.919

9.  Therapeutic efficacy of a respiratory syncytial virus fusion inhibitor.

Authors:  Dirk Roymans; Sarhad S Alnajjar; Michael B Battles; Panchan Sitthicharoenchai; Polina Furmanova-Hollenstein; Peter Rigaux; Joke Van den Berg; Leen Kwanten; Marcia Van Ginderen; Nick Verheyen; Luc Vranckx; Steffen Jaensch; Eric Arnoult; Richard Voorzaat; Jack M Gallup; Alejandro Larios-Mora; Marjolein Crabbe; Dymphy Huntjens; Pierre Raboisson; Johannes P Langedijk; Mark R Ackermann; Jason S McLellan; Sandrine Vendeville; Anil Koul
Journal:  Nat Commun       Date:  2017-08-01       Impact factor: 14.919

10.  Anti-RSV Peptide-Loaded Liposomes for the Inhibition of Respiratory Syncytial Virus.

Authors:  Sameer Joshi; Atul A Chaudhari; Vida Dennis; Daniel J Kirby; Yvonne Perrie; Shree Ram Singh
Journal:  Bioengineering (Basel)       Date:  2018-05-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.